Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Endocytosis Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SNX9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SNX9 Recombinant Protein (Full-Length / SH3 Domain / PX-BAR Domains) High purity (>95%), Endotoxin Controlled. Sequence Verified. E. coli or Eukaryotic expression. |
View SNX9 Products |
| Gene Delivery | SNX9 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View SNX9 Products |
| Benchmark Ab | Anti-SNX9 Recombinant Antibody Recombinant positive control for immunoprecipitation, Western Blot, and IHC. |
View SNX9 Products |
| Validator | SNX9 siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View SNX9 Products |
| Related Target A | DNM2 (Dynamin-2) Direct binding partner of SNX9 SH3 domain; critical for vesicle scission during endocytosis. |
View DNM2 Products |
| Related Target B | WASL (N-WASP) Interacts with SNX9 to promote actin polymerization during membrane remodeling and cancer cell invasion. |
View WASL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Recombinant multi-domain protein stability (SH3-PX-BAR) | Sequence Verified, High Purity (>95%) by SDS-PAGE, and Theoretical MW confirmed by MS. |
| Protein-Protein Interaction (PPI) screening (SNX9-DNM2 / SNX9-WASL) | Domain-specific recombinant proteins (e.g., isolated SH3 domain) optimized for binding assays. |
| Lack of Controls | Sequence-derived recombinant benchmark antibodies included for assay validation. |
| False Positives | Sequence-verified siRNA pools included for target-specific knockdown controls. |
Live SNX9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SNX9 therapeutics is intensifying, with major players shifting focus from traditional mAbs to intracellular small molecule inhibitors and RNA-targeting modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the SNX9-Dynamin-2 complex to inhibit cancer cell invasion and metastasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Breast Cancer Metastasis, Prostate Cancer | PPI Disruption Assay (Need high-purity SH3 domain and full-length proteins) |
| RNAi (siRNA/shRNA) | RNA Therapeutics Specialists | Solid Tumors, Viral Infections (Host Factor) | Knockdown Validation (Need sequence-verified siRNA sets & Lentivirus) |
| Gene Therapy / CRISPR | Preclinical Research Labs | Endocytosis Disorders, Rare Diseases | Stable Cell Line Construction (Need high-titer Lentivirus Premade Particles) |